Nano & wastewater : volumetry in biomedical publications since 2000

This chart was built by searching PubMed for publications mentionning the prefix nano and wastewater topic in their title or abstract.

New clinical trial : personalized medicine in diabetes using a nanotechnology platform

Rambam Health Care Campus in Israel will launch in collaboration with Technion/Israel Institute of Technology a phase I clinical trial about “personalized medicine in diabetes using a nanotechnology platform”, registered in the Clinicaltrials.gov database under reference NCT01268813. In this trial, breath samples will be collected in inert respiratory bag from diabetic and healthy volunteers, and analyzed using a chamber containing nano-chemical sensors. These samples together with blood samples will additionally be characterized using Gas Chromatography-Mass Spectroscopy (GC-MS). The study is not yet open for participant recruitment.

New clinical trial : in vivo assessment of silver biomaterial nanotoxicity

University of Utah will launch a phase I / phase II clinical trial to assess silver biomaterial nanotoxicity in healthy human volunteers, registered in the Clinicaltrials.gov database under reference NCT01243320. The purpose of the trial is to :

– quantify comprehensive metabolic panel, urinalysis, and CBC with platelet count changes from exposure to 10 ppm silver solution ;

-quantify silver in whole blood and urine by measurement of silver metallic ions (Ag0) ;

-quantify granulocyte and agranulocyte counts, measuring presence of reactive oxygen species (ROS), and determining presence of pro-inflammatory genetic markers from induced sputum ;

-qualify silver nanoparticle retention in human organ systems (on the last day of each phase of the study, all eligible subjects without will undergo a cardiac and abdominal MRI to identify retention Ag0 nanoparticles).

The study is not yet open for participant recruitment.

[[[ Additional links suggested by Nanocolors :

# Silver nanoparticles in biomedical publications since 2000

# Nanomaterials and toxicity in biomedical publications since 2000 ]]]

New clinical trial – Abraxane and carboplatin as first-line treatment for triple negative metastatic breast cancer

Duke University and Abraxis Bioscience recently started a phase II clinical trial involving Abraxane (nanoparticle albumin-bound paclitaxel), now registered in the Clinicaltrials.gov database under reference NCT01207102. The primary objective of the trial is to statistically test whether Abraxane and carboplatin can improve progression-free survival as first-line treatment for “triple negative” (no expression for estrogen, progesterone, or HER2 receptors) metastatic breast cancer. The study is not yet open for participant recruitment.

[[[ Additional links suggested by Nanocolors :

Nanoparticles & cancer therapy : volumetry in biomedical publications since 2000

Nanoparticles in clinical trial trends : comments & focus on Abraxane ]]]

Nano & French university patents : Université Claude Bernard (Lyon) ranks 1st

This chart was built by searching the Espacenet database for patents

1) mentionning the prefix “nano” in their title or abstract

2) mentionning “univ”, the [FR] country code, and the name of the university in the “applicant” field

3) without any restriction of publication year

Only the top 10 most visible French universities according to these criteria are presented in the chart (NB : total number of patents is much lower than for US universities)

Nano & US university patents : strong Californian leadership, Rice University comes second

This chart was built by searching the Espacenet database for patents

1) mentionning the prefix “nano” in their title or abstract

2) mentionning “univ”, the [US] country code, and the name of the university in the “applicant” field

3) without any restriction of publication year

Only the top 10 most visible US universities according to these criteria are presented in the chart.

University nanotechnology patents : China, USA and Korea most productive countries

This chart was built by searching the Espacenet database for patents

1) mentionning the prefix “nano” in their title or abstract

2) mentionning “univ” and the country code in the “applicant” field

3) without any restriction of publication year

Only the top 10 most visible countries according to these criteria are presented in the chart.

Top ten journals in nanoscience and nanotechnology

According to this blog post, the top 10 journals in nanoscience and nanotechnology – based on 2008 impact factors – are :

1. Nature Nanotechnology, Impact Factor = 20.571
2. Nano Letters, Impact Factor = 10.371
3. Nano Today, Impact Factor = 8.795
4. Small, Impact Factor = 6.525
5. Lab on a Chip, Impact Factor = 6.478
6. Nanomedicine, Impact Factor = 6.093
7. ACS Nano, Impact Factor = 5.472
8. Biosensors & Bioelectronics, Impact Factor = 5.143
9. Nanotoxicology, Impact Factor = 3.720
10. Plasmonics, Impact Factor = 3.488

USA risk losing global leadership in nanotech

According to a new report from Lux Research, “In terms of sheer volume, The U.S. dominated the rest of the world in nanotech funding and new patents last year (…). But (…) countries such as China and Russia launched new challenges to U.S. dominance in 2009, while smaller players such as Japan, Germany and South Korea surpassed the United States in terms of commercializing nanotechnology and products.” (press release)

 [[[ Additional links suggested by Nanocolors :

Has China already passed America in nanotechnology?

Nano-related patents – the most visible countries 

Ranking the nations on nanotech ]]]

New clinical trial – capsaicin nanoparticles in patients with painful diabetic neuropathy

Mahidol University and the Thailand Research Fund recently started a phase II/III clinical trial involving a capsaicin nanoparticle preparation, now registered in the Clinicaltrials.gov database under reference NCT01125215. According to this page, the aim is to “determine efficacy and safety of 0.75% topical capsaicin nanoparticle preparation versus placebo in patient with painful diabetic neuropathy“. The study is currently recruiting participants.